Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.
There are proposals for the implementation of beta(2)-adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that beta(2)-adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart beta(2)-adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients.
Molenaar
Peter
P
Discipline of Medicine, The University of Queensland, The Prince Charles Hospital, Chermside, Queensland 4032, Australia. p.molenaar@mailbox.uq.edu.au
Chen
Lu
L
Parsonage
William A
WA
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D009136:Muscular Dystrophies / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism; D018342:Receptors, Adrenergic, beta-1 / Q000378:metabolism; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2